Acute Respiratory Support
INSPIRA™ ART
Targets to boost and stabilize oxygen saturation levels to 95% or higher in minutes without a mechanical ventilator, and while the patient is awake.
The Solution to the Respiratory Gap
The Solution
to the Respiratory Gap
to the Respiratory Gap
Doctors facing patients with treatment challenges administer supplemental oxygen using devices such as nasal cannulas, and, when supplemental treatment is insufficient, their only option is to induce coma, intubate and place the patient on mechanical ventilator. The INSPIRA ART bridges this gap, targets to solve the respiratory gap between supplemental respiratory care and mechanical ventilation that should be used as a treatment of last resort
Nasal Cannula
INSPIRA™ ART
Mechanical Ventilation
Adaptive Blood Oxygenation Technology.
Patient Treated While Awake.
The adaptive technology is designed to continuously monitor the patient's blood parameters in real-time, enriching small volumes of blood with oxygen and simultaneously removing carbon dioxide.
Boosting oxygen saturation levels in minutes, may allow patients to be awake, potentially making the treatment suitable in the future to migrate from intensive care units to Emergency Rooms, Medical Units, Emergency Medical Services and smaller rural hospitals.
Boosting oxygen saturation levels in minutes, may allow patients to be awake, potentially making the treatment suitable in the future to migrate from intensive care units to Emergency Rooms, Medical Units, Emergency Medical Services and smaller rural hospitals.
HYLA™ Clip-On Blood Lab
Without the need to take intermittent blood samples, the HYLA™ Optic Blood Lab is designed to test, monitor and alert of sudden changes in key blood parameters.
The HYLA™ Blood Sensor is designed to perform real-time analyzing of blood gases, for patients undergoing medical procedures or requiring more frequent patient monitoring.
The HYLA™ Blood Sensor is designed to perform real-time analyzing of blood gases, for patients undergoing medical procedures or requiring more frequent patient monitoring.
In Clinical Evaluation. Planned FDA Submission H1-2025
VORTX™ Oxygen Delivery
The VORTX™ technology is designed to enrich small volumes of blood with oxygen and simultaneously remove carbon dioxide to elevate saturation levels to 95% or higher.
The VORTX™ aims to oxygenate blood without fiber membranes, known to cause harmful turbulence, friction, and shear forces, increasing damage to blood cells and clotting
The VORTX™ aims to oxygenate blood without fiber membranes, known to cause harmful turbulence, friction, and shear forces, increasing damage to blood cells and clotting
Multiple Patents. A total of 32 Novel Claims
Dual Lumen Cannula
16 Novel Claims
The proprietary Convertible Dual Lumen Cannula is uniquely designed to offer multiple uses with intravascularly converting from a single-lumen cannula into a dual-lumen cannula after initial insertion. The unique cannula may potentially allow for fast action and reduced risk, complications and additional infection points.
An essential tool in a wide range of medical settings
A dual-lumen cannula is often used for the simultaneous venous drainage and reinfusion of blood during processes such Extra-Corporeal Membrane Oxygenation (ECMO) in Intensive Care Units (ICUs).
An essential tool in a wide range of medical settings
A dual-lumen cannula is often used for the simultaneous venous drainage and reinfusion of blood during processes such Extra-Corporeal Membrane Oxygenation (ECMO) in Intensive Care Units (ICUs).
Inspira™ Patent Portfolio and Technologies
Extracorporeal oxygenation system
For low flow rates and methods of use
- Granted in the U.S., 2023*
- Filed in the U.S., Canada, Europe, China, Korea, Japan, Australia, Brazil, Israel
VORTX™
Orbiting blood oxygenation delivery
A blood-gas exchange device and methods of use
- Granted in the U.S. 2024
- 36 Novel Claims
Dual lumen cannula
- Granted in the U.S., 2023*
- Granted in the U.S., 2023
- Filed in Europe, China, Korea, Japan, Israel
A cannula fixation device
- Granted in the U.S. 2024
- Granted in Israel, 2022
Bio-Electronic Technology
Inspira has partnered with Ennocure to develop bio-electronic technology to prevent the accumulation of bacteria that often results in a bloodstream infection (sepsis).
As part of the INSPIRA ART and Company's IP portfolio, the bio-electronic novel physical stimulation technology, is designed to be a preemptive measure for potentially at-risk patients, providing a cost-competitive solution to reduce associated risks, complications and hospital days.
As part of the INSPIRA ART and Company's IP portfolio, the bio-electronic novel physical stimulation technology, is designed to be a preemptive measure for potentially at-risk patients, providing a cost-competitive solution to reduce associated risks, complications and hospital days.
